June 5, 2017

ANGLE plc (AIM:AGL OTCQX:ANPCY), the specialist medtech company, is pleased to announce that researchers have presented successful results from their work using ANGLE’s Parsortix system in colorectal cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017, in Chicago.

The study, undertaken by The University of Texas MD Anderson Cancer Center, represents the first ever analysis of meEGFR (arginine methylation of the epidermal growth factor receptor) status across a population of circulating tumour cells (CTCs) isolated from colorectal cancer patients being treated with EGFR inhibitors. meEGFR is already associated with a patient’s likely response to EGFR inhibitors, a key drug class in the treatment of colorectal cancer. The object of the study was therefore to assess whether the presence of meEGFR biomarker, when found in CTCs, is predictive of an adverse duration of progression-free survival (PFS) amongst this treatment group.  

The results show that in a prospective study of 47 metastatic colorectal cancer patients, researchers were able to use the Parsortix system to harvest circulating tumour cells (CTCs) and were able to analyse these cells for the presence or absence of meEGFR.

The total number of CTCs was not correlated to PFS but the proportion of those CTCs that were positive for the meEGFR marker was found to be predictive: patients whose CTCs harvested by Parsortix had a higher proportion of meEGFR positive CTCs, had significantly shorter PFS compared to those patients whose CTCs had lower levels.

This study is a further demonstration of the effectiveness of Parsortix in enabling liquid biopsy analysis of patients’ cancer through a simple blood test with the potential to provide clinically relevant information to advise treatment decisions. 


Dr Scott Kopetz, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, MD Anderson, commented:

“We have isolated CTCs from metastatic colorectal cancer patients’ blood using the Parsortix system and then identified and assessed the CTCs for the presence of the meEGFR marker.  This could open the opportunity for a liquid biopsy biomarker for reduced efficacy from anti-EGFR treatments.”

ANGLE Founder and Chief Executive, Andrew Newland, commented:

“This colorectal cancer study adds to the body of evidence driving adoption of Parsortix in the fast growing liquid biopsy market.  The ability to assess the patient’s likely response to a particular drug as a companion diagnostic is a key element in the drive to provide precision medicine for patients saving money and improving treatment.”

Back to Latest News